Zynex (NASDAQ:ZYXI) Issues FY 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.200- for the period, compared to the consensus estimate of 0.200. The company issued revenue guidance of $200.0 million-, compared to the consensus revenue estimate of $200.5 million. Zynex also updated its Q4 guidance to at least $0.09 EPS.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ZYXI shares. Royal Bank of Canada reduced their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright upped their target price on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday.

Zynex Stock Performance

Shares of Zynex stock traded up $0.53 during trading hours on Friday, hitting $9.12. 264,477 shares of the company were exchanged, compared to its average volume of 173,892. The business has a 50-day moving average of $8.01 and a 200-day moving average of $9.20. Zynex has a 1 year low of $7.04 and a 1 year high of $13.77. The company has a current ratio of 4.06, a quick ratio of 3.22 and a debt-to-equity ratio of 1.79. The stock has a market capitalization of $289.47 million, a price-to-earnings ratio of 50.67 and a beta of 0.54.

Zynex (NASDAQ:ZYXI) last released its earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Zynex had a net margin of 3.12% and a return on equity of 14.15%. The company had revenue of $49.97 million during the quarter, compared to analysts’ expectations of $50.83 million. During the same quarter last year, the business earned $0.10 EPS. The business’s revenue was up .1% on a year-over-year basis. As a group, analysts expect that Zynex will post 0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zynex news, Director Joshua R. Disbrow purchased 7,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were purchased at an average cost of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the purchase, the director now directly owns 72,000 shares in the company, valued at $599,040. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Anna Lucsok sold 8,083 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $8.03, for a total value of $64,906.49. Following the sale, the chief operating officer now owns 16,980 shares in the company, valued at $136,349.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Joshua R. Disbrow acquired 7,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average price of $8.32 per share, for a total transaction of $58,240.00. Following the completion of the transaction, the director now directly owns 72,000 shares in the company, valued at approximately $599,040. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 52.13% of the stock is currently owned by insiders.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.